AQST EBITDA
-$61.39MTTM · USD
Period ending:
AQST FY EBITDAUSD
$2.95M-$66.14M
2016-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
AQST ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 10 observations from Dec 31, 2016 to Dec 31, 2025.
| Period ending | EBITDA (USD) |
|---|---|
| -66,136,000 | |
| -26,616,000 | |
| 1,182,000 | |
| -39,580,000 | |
| -45,114,000 | |
| -39,318,000 | |
| -54,023,000 | |
| -50,429,000 | |
| 2,565,000 | |
| 2,945,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All AQST financial metrics · AQST stock overview · How to interpret financial metrics
